Premier Path Wealth Partners, LLC Arbutus Biopharma Corp Transaction History
Premier Path Wealth Partners, LLC
- $718 Billion
- Q2 2025
A detailed history of Premier Path Wealth Partners, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Premier Path Wealth Partners, LLC holds 40,000 shares of ABUS stock, worth $136,000. This represents 0.02% of its overall portfolio holdings.
Number of Shares
40,000
Previous 40,000
-0.0%
Holding current value
$136,000
Previous $140 Million
11.46%
% of portfolio
0.02%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding ABUS
# of Institutions
189Shares Held
112MCall Options Held
861KPut Options Held
708K-
Morgan Stanley New York, NY23.8MShares$80.9 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$45.2 Million27.3% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$39.3 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.47MShares$32.2 Million1.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$30.9 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $510M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...